Inhaled placental cell particles for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new inhaled therapy made from tiny particles derived from placental cells, which may help reduce scarring in the lungs. It is a phase 1 study, so the main goal is to check safety and see if the treatment has any effect on IPF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of IPF (a specific type of lung scarring).
- Your lung function must be within a certain range (FVC 50–80% of predicted and DLCO 30–80%).
- You must be on a stable dose of your current IPF medication for at least 8 weeks.
- You must be able to walk more than 150 meters in 6 minutes.
- You must not have had stem cell therapy before and must not have asthma or other active lung diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.